We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sandoz’s Preemptive Biosimilar Bid Against Amgen’s Enbrel Dismissed
Sandoz’s Preemptive Biosimilar Bid Against Amgen’s Enbrel Dismissed
Sandoz’s bid to invalidate two patents protecting Amgen’s biologic rheumatoid arthritis therapy Enbrel was dealt a major blow last month after a federal appeals court affirmed that a patent challenge prior to submission of a biosimilar application is premature.